This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Public Health, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2008;300(17):1985-1986.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The increasing use of direct-to-consumer advertising of medical devices is making some physicians and legislators uneasy.

They question whether the public can truly comprehend, based on 60-second television commercials, ad pages in newspapers and popular magazines, or Internet pages, the benefits and risks of such device-based medical interventions as a total hip replacement or the use of stents in a percutaneous coronary intervention. They also are raising questions about how the US Food and Drug Administration (FDA) will handle its regulatory role over device advertising.

These concerns were highlighted in a Senate Special Committee on Aging hearing on September 17 called by committee chairman Sen Herb Kohl (D, Wis). Kohl has convened a series of oversight hearings exploring medical device and pharmaceutical marketing. "As with direct-to-consumer drug ads, the FDA has raised concerns about advertising restricted [not over-the-counter] medical devices; specifically, about whether appropriate risk and safety information . . . [Full Text of this Article]

A GROWING PRESENCE



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Medicine as Ecoculture
Gillick
ANN INTERN MED 2009;151:577-580.
ABSTRACT | FULL TEXT